Year-end Sale % OFF 
Abstract
Introduction: In RAS wild-type colorectal cancer, the anti-EGFR monoclonal antibody cetuximab has shown activity in various therapeutic settings, and has been successfully combined with different conventional chemotherapy regimens in randomized trials, including irinotecanand oxaliplatin-based regimens. Subgroup analysis of the MRC COIN trial showed that cetuximab had a detrimental effect on combination with oral fluoropyrimidine (FU), capecitabine and oxaliplatin and the use of cetuximab in combination with capecitabine and oxaliplatin is accordingly not recommended. Furthermore, an infusional FU regimen is regarded as a more optimal backbone for the addition of cetuximab. S-1 is a new oral anticancer drug that combines tegafur, a prodrug of fluorouracil, with 5-chloro-2,4-dihydropyrimidine (CDHP), and potassium oxonate in a molar ration of 1:0.4:1. S-1 has shown an anti-cancer effect on combination with oxaliplatin (SOX regimen) or irinotecan (IRIS regimen) for colorectal cancer. Here, we evaluated the efficacy and safety of cetuximab in combination with oral FU-based regimens compared with infusional FU-based regimens.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
